Novo Nordisk Accelerates $2.34B Expansion of Italian Manufacturing Site

Novo Nordisk is set to invest €2.34 billion in upgrading its pharmaceutical facility in Anagni, near Rome, aiming to enhance production of diabetes and weight loss medications. Acquired through Novo Holdings' 2024 takeover of Catalent, the Anagni site is central to Novo Nordisk's strategy to meet growing global demand for treatments like semaglutide-based therapies. 

To expedite the project, Italian authorities have appointed Francesco Rocca, president of the Lazio region, as a special commissioner, granting him powers to streamline administrative processes. The initiative has been designated as a project of "pre-eminent strategic interest," facilitating faster approvals. Production is expected to commence between late 2026 and early 2027, with full completion anticipated by 2029. 

The expansion will create approximately 800 new jobs, increasing the site's workforce to 1,500. Additionally, the Lazio region has approved over €2.9 million in infrastructure improvements to support the facility.